THALES
7.6.2022 09:02:10 CEST | Business Wire | Press release
The 2022 Thales Cloud Security Report , conducted by 451 Research, part of S&P Global Market Intelligence, reports that 45% of businesses have experienced a cloud-based data breach or failed audit in the past 12 months, up 5% from the previous year1 , raising even greater concerns regarding to protecting sensitive data from cybercriminals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005059/en/
Globally, cloud adoption and notably multicloud adoption, remains on the rise. In 2021, organisations worldwide were using an average amount of 110 software as a service (SaaS) applications2 , compared with just eight in 2015, showcasing a startlingly rapid increase. There has been a notable expansion in the use of multiple IaaS providers, with almost three-quarters (72%) of businesses using multiple IaaS providers, up from 57% the year before. The use of multiple providers has almost doubled in the last year, with one in five (20%) of respondents reporting using three or more providers.
Despite their increasing prevalence and use, businesses share common concerns about the increasing complexity of cloud services with the majority (51%) of IT professionals agreeing that it is more complex to manage privacy and data protection in the cloud. Additionally, the journey to the cloud is also becoming more complex, with the percentage of respondents reporting that they’re expecting to lift and shift, the simplest of migration tactics, dropping from 55% in 2021 to 24% currently.
Security Challenges of Multicloud Complexity
With increasing complexity comes an even greater need for robust cybersecurity. When asked what percentage of their sensitive data is stored in the cloud, a solid majority (66%) said between 21-60%. However, only a quarter (25%) said they could fully classify all data.
Additionally, nearly a third (32%) of respondents admitted to having to issue a breach notification to a government agency, customer, partner or employees. This should be a cause for concern among enterprises with sensitive data, particularly in highly regulated industries.
Cyber-attacks also present an ongoing risk to cloud applications and data. Respondents reported an increasing prevalence of attacks, with a quarter (26%) citing an increase in malware, 25% in ransomware and one-fifth (19%) reporting seeing an increase in phishing/ whaling.
Protecting Sensitive Data
When it comes to securing data in multicloud environments, IT professionals view encryption as a critical security control. The majority of respondents cited encryption (59%) and key management (52%) as the security technologies they currently use to protect sensitive data in the cloud.
However, when asked what percentage of their data in the cloud is encrypted, only one in ten (11%) of respondents said between 81-100% is encrypted. Additionally, key management platform sprawl may be an issue for enterprises. Only 10% of respondents use one to two platforms, 90% use three or more, and almost one in five (17%) admitted using eight or more platforms.
Encryption should be a priority area for enterprises to focus on when it comes to securing data in the cloud. In fact, 40% of respondents stated that they were able to avoid the breach notification process because the stolen or leaked data was encrypted or tokenised, showcasing the tangible value of encryption platforms.
Additionally, it is encouraging to see signs enterprises embrace Zero Trust and investing accordingly. Nearly a third of respondents (29%) said they are already executing a Zero Trust strategy, a quarter (27%) said they are evaluating and planning one and, 23% said they are considering it. This is a positive result, but there is certainly still room to grow.
Sebastien Cano, Senior Vice President for Cloud Protection and Licensing activities at Thales said: “The complexity of managing multicloud environments cannot be overstated. Additionally, the growing importance of data sovereignty is increasingly raising questions for CISOs and Data Protection Officers when considering their cloud strategy, governance, and risk management. The challenge is not only where the sensitive data resides geographically, but even who has access to sensitive data inside the organisation.
There are various solutions such as encryption and key management. Last but not least, continuing to embrace a Zero Trust strategy will be essential in securing these complex environments, helping to ensure organisations can support their data and manage future challenges.”
Thales and 451 Research will discuss the findings in more detail during a webinar on 23 June 2022. To join, please visit the registration page .
About the 2022 Thales Global Cloud Security Study
As organizations step beyond the urgent actions of the last two years, they’re grappling with securing the more complex environments in which they now operate. The global edition of the 2022 Thales Cloud Security Study looked at various aspects of those impacts in a wide-ranging survey of security professionals and executive leadership that touched on issues including accelerated digital transformation, cloud migration, and the complexities of managing security in a multicloud world. The 2022 Thales Cloud Security Study is based on data from a survey of almost 2,800 security professionals and executive leaders. This research was conducted as an observational study and makes no causal claims.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
PLEASE VISIT
1
https://cpl.thalesgroup.com/cloud-security-research
2
https://www.statista.com/statistics/1233538/average-number-saas-apps-yearly/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
